Sirion Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2005-01-01
- Employees
- 101
- Market Cap
- -
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Sirion Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00406497
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Sirion Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00407056
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Sirion Therapeutics, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT00406887
Study of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2006-12-04
- Lead Sponsor
- Sirion Therapeutics, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT00406341
Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-11-30
- Last Posted Date
- 2006-11-30
- Lead Sponsor
- Sirion Therapeutics, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00405496
© Copyright 2024. All Rights Reserved by MedPath